|
1
|
Kyle RA and Rajkumar SV: Criteria for
diagnosis, staging, risk stratification and response assessment of
multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corre J, Mahtouk K, Attal M, Gadelorge M,
Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème
T and Bourin P: Bone marrow mesenchymal stem cells are abnormal in
multiple myeloma. Leukemia. 21:1079–1088. 2007.PubMed/NCBI
|
|
3
|
Hromas R, Hufford M, Sutton J, Xu D, Li Y
and Lu L: PLAB, a novel placental bone morphogenetic protein.
Biochim Biophys Acta. 1354:40–44. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paralkar VM, Vail AL, Grasser WA, Brown
TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA and Thompson DD:
Cloning and characterization of a novel member of the transforming
growth factor-beta/bone morphogenetic protein family. J Biol Chem.
273:13760–13767. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Böttner M, Suter-Crazzolara C, Schober A
and Unsicker K: Expression of a novel member of the TGF-beta
superfamily, growth/differentiation factor-15/macrophage-inhibiting
cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res.
297:103–110. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baek SJ, Horowitz JM and Eling TE:
Molecular cloning and characterization of human nonsteroidal
anti-inflammatory drug-activated gene promoter. Basal transcription
is mediated by Sp1 and Sp3. J Biol Chem. 276:33384–33392. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bootcov MR, Bauskin AR, Valenzuela SM,
Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor
K, et al: Mic-1, a novel macrophage inhibitory cytokine, is a
divergent member of the TGF-beta superfamily. Proc Natl Acad Sci
USA. 94:11514–11519. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tarkun P, Atesoglu E Birtas, Mehtap O,
Musul MM and Hacihanefioglu A: Serum growth differentiation factor
15 levels in newly diagnosed multiple myeloma patients. Acta
Haematol. 131:173–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wakchoure S, Swain TM, Hentunen TA,
Bauskin AR, Brown DA, Breit SN, Vuopala KS, Harris KW and Selander
KS: Expression of macrophage inhibitory cytokine-1 in prostate
cancer bone metastases induces osteoclast activation and weight
loss. Prostate. 69:652–661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng Z, Zhang C and Chen J:
Lentivirus-mediated RNA interference of DC-STAMP expression
inhibits the fusion and resorptive activity of human osteoclasts. J
Bone Miner Metab. 31:409–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roodman GD: Pathogenesis of myeloma bone
disease. Leukemia. 23:435–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khosla S: Minireview: The OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sung B, Prasad S, Yadav VR, Gupta SC,
Reuter S, Yamamoto N, Murakami A and Aggarwal BB: RANKL signaling
and osteoclastogenesis is negatively regulated by cardamonin. PLoS
One. 8:e641182013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong YY, Yoshida H, Sarosi I, Tan HL,
Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G,
Itie A, et al: OPGL is a key regulator of osteoclastogenesis,
lymphocyte development and lymph-node organogenesis. Nature.
397:315–323. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schramek D, Leibbrandt A, Sigl V, Kenner
L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A,
Glimcher L, et al: Osteoclast differentiation factor RANKL controls
development of progestin-driven mammary cancer. Nature. 468:98–102.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sung B, Oyajobi B and Aggarwal BB:
Plumbagin inhibits osteoclastogenesis and reduces human breast
cancer-induced osteolytic bone metastasis in mice through
suppression of RANKL signaling. Mol Cancer Ther. 11:350–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ai LS, Sun CY, Zhang L, Zhou SC, Chu ZB,
Qin Y, Wang YD, Zeng W, Yan H, Guo T, et al: Inhibition of BDNF in
multiple myeloma blocks osteoclastogenesis via down-regulated
stroma-derived RANKL expression both in vitro and in vivo. PLoS
One. 7:e462872012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wada T, Nakashima T, Hiroshi N and
Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone
disease. Trends Mol Med. 12:17–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang P, Han J and Hui L: MAPK signaling
in inflammation-associated cancer development. Protein Cell.
1:218–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng X: RANKing intracellular signaling in
osteoclasts. IUBMB Life. 57:389–395. 2005. View Article : Google Scholar : PubMed/NCBI
|
